NKTR
Nektar Therapeutics
Price Chart
Latest Quote
$66.69
+0.99 (+1.51%)
Current Price
| Previous Close | $65.70 |
| Open | $64.10 |
| Day High | $67.79 |
| Day Low | $64.10 |
| Volume | 785,315 |
Stock Information
| Shares Outstanding | 33.79M |
| Total Debt | $143.43M |
| Cash Equivalents | $568.60M |
| Revenue | $55.63M |
| Net Income | $-158.10M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.25B |
| EPS (TTM) | $-8.05 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.83B |
| Sales | $55.63M |
| Income | $-158.10M |
| Book/sh | $19.55 |
| Cash/sh | $16.83 |
| Employees | 63 |
Financial Ratios
| Quick Ratio | 9.92 |
| Current Ratio | 10.21 |
| Debt/Eq | 24.89 |
Returns & Margins
| ROA | -15.29% |
| ROE | -53.60% |
| Gross Margin | 100.00% |
| Operating Margin | -352.25% |
| Profit Margin | -284.18% |
Ownership
| Insider Ownership | 0.45% |
| Institutional Ownership | 80.14% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.31 |
| PEG | 0.31 |
| P/S | 40.50 |
| P/B | 3.41 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $153.25 |
Technical Indicators
| SMA20 | $61.15 |
| SMA50 | $73.54 |
| SMA200 | $61.08 |
| RSI | 75.33 |
| ATR | 3.0257 |
| Shares Float | 29.14M |
| Short Float | 15.07% |
| Short Ratio | 5.37 |
| Volatility | 1.15 |
| Rel Volume | 0.80 |
Performance History
| Week | +9.06% |
| Month | -2.76% |
| Quarter | -10.29% |
| 6 Months | +51.57% |
| YTD | +53.59% |
| Year | +683.67% |
| 3 Years | +693.93% |
| 5 Years | -74.95% |
| 10 Years | -69.08% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $66.69 | 785,315 |
| 2026-06-22 | $65.70 | 1,404,600 |
| 2026-06-18 | $60.98 | 909,600 |
| 2026-06-17 | $60.92 | 676,700 |
| 2026-06-16 | $60.27 | 725,600 |
| 2026-06-15 | $61.15 | 674,200 |
| 2026-06-12 | $59.38 | 534,200 |
| 2026-06-11 | $59.21 | 794,800 |
| 2026-06-10 | $56.78 | 874,100 |
| 2026-06-09 | $56.23 | 1,173,300 |
| 2026-06-08 | $56.62 | 1,000,100 |
| 2026-06-05 | $57.32 | 1,033,700 |
| 2026-06-04 | $59.31 | 1,136,400 |
| 2026-06-03 | $59.23 | 920,900 |
| 2026-06-02 | $58.56 | 2,151,400 |
| 2026-06-01 | $63.86 | 871,000 |
| 2026-05-29 | $64.88 | 973,400 |
| 2026-05-28 | $65.01 | 671,300 |
| 2026-05-27 | $65.40 | 1,412,100 |
| 2026-05-26 | $65.56 | 879,300 |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
đ° Latest News
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
24/7 Wall St. âĸ 2026-06-23T11:55:41Z
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility
Simply Wall St. âĸ 2026-06-07T03:10:23Z
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock
Insider Monkey âĸ 2026-06-05T15:55:48Z
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
Motley Fool âĸ 2026-05-23T20:48:41Z
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
Motley Fool âĸ 2026-05-23T20:37:22Z
Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum
Simply Wall St. âĸ 2026-05-13T00:26:58Z
Nektar Therapeutics Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Nektar Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T11:07:36Z
Nektar (NKTR) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-07T22:53:29Z
How The Rezpegaldesleukin Story Is Recasting The Narrative For Nektar Therapeutics (NKTR)
Simply Wall St. âĸ 2026-05-02T16:14:22Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $0 | $30,686,000 | $33,768,000 | $21,635,000 |
| Cost Of Revenue | $0 | $30,686,000 | $33,768,000 | $21,635,000 |
| Total Revenue | $55,232,000 | $98,427,000 | $90,122,000 | $92,055,000 |
| Operating Revenue | $55,232,000 | $98,427,000 | $90,122,000 | $92,055,000 |
| Expenses | ||||
| Interest Expense | $26,184,000 | $28,112,000 | $25,334,000 | $28,911,000 |
| Total Expenses | $186,003,000 | $228,345,000 | $225,347,000 | $332,291,000 |
| Other Income Expense | $-8,970,000 | $24,330,000 | $-134,706,000 | $-102,619,000 |
| Other Non Operating Income Expenses | $361,000 | $-390,000 | $-6,247,000 | $-116,000 |
| Net Non Operating Interest Income Expense | $-15,746,000 | $-13,612,000 | $-6,325,000 | $-22,128,000 |
| Interest Expense Non Operating | $26,184,000 | $28,112,000 | $25,334,000 | $28,911,000 |
| Operating Expense | $186,003,000 | $197,659,000 | $191,579,000 | $310,656,000 |
| General And Administrative Expense | $68,673,000 | $76,751,000 | $77,417,000 | $92,333,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-164,076,000 | $-118,961,000 | $-276,056,000 | $-368,198,000 |
| Net Interest Income | $-15,746,000 | $-13,612,000 | $-6,325,000 | $-22,128,000 |
| Interest Income | $10,438,000 | $14,500,000 | $19,009,000 | $6,783,000 |
| Normalized Income | $-154,754,331 | $-143,631,560 | $-147,690,000 | $-287,220,630 |
| Net Income From Continuing And Discontinued Operation | $-164,076,000 | $-118,961,000 | $-276,056,000 | $-368,198,000 |
| Total Operating Income As Reported | $-140,102,000 | $-105,198,000 | $-263,684,000 | $-376,166,000 |
| Net Income Common Stockholders | $-164,076,000 | $-118,961,000 | $-276,056,000 | $-368,198,000 |
| Net Income | $-164,076,000 | $-118,961,000 | $-276,056,000 | $-368,198,000 |
| Net Income Including Noncontrolling Interests | $-164,076,000 | $-118,961,000 | $-276,056,000 | $-368,198,000 |
| Net Income Continuous Operations | $-164,076,000 | $-118,961,000 | $-276,056,000 | $-368,198,000 |
| Earnings From Equity Interest Net Of Tax | $-8,727,000 | $0 | - | - |
| Pretax Income | $-155,487,000 | $-119,200,000 | $-276,256,000 | $-364,983,000 |
| Special Income Charges | $-9,331,000 | $24,720,000 | $-128,459,000 | $-135,930,000 |
| Interest Income Non Operating | $10,438,000 | $14,500,000 | $19,009,000 | $6,783,000 |
| Operating Income | $-130,771,000 | $-129,918,000 | $-135,225,000 | $-240,236,000 |
| Gross Profit | $55,232,000 | $67,741,000 | $56,354,000 | $70,420,000 |
| Per Share | ||||
| Diluted EPS | $-9.73 | $-8.70 | $-21.75 | $-29.55 |
| Basic EPS | $-9.73 | $-8.70 | $-21.75 | $-29.55 |
| Other | ||||
| Tax Effect Of Unusual Items | $-9,331 | $49,440 | $-93,000 | $-21,525,630 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-118,946,000 | $-111,417,000 | $-114,648,000 | $-220,539,000 |
| Total Unusual Items | $-9,331,000 | $24,720,000 | $-128,459,000 | $-102,503,000 |
| Total Unusual Items Excluding Goodwill | $-9,331,000 | $24,720,000 | $-128,459,000 | $-102,503,000 |
| Reconciled Depreciation | $1,026,000 | $4,391,000 | $7,815,000 | $13,030,000 |
| EBITDA (Bullshit earnings) | $-128,277,000 | $-86,697,000 | $-243,107,000 | $-323,042,000 |
| EBIT | $-129,303,000 | $-91,088,000 | $-250,922,000 | $-336,072,000 |
| Diluted Average Shares | $16,870,930 | $13,710,733 | $12,666,733 | $12,475,866 |
| Basic Average Shares | $16,870,930 | $13,710,733 | $12,666,733 | $12,475,866 |
| Diluted NI Availto Com Stockholders | $-164,076,000 | $-118,961,000 | $-276,056,000 | $-368,198,000 |
| Tax Provision | $-138,000 | $-239,000 | $-200,000 | $3,215,000 |
| Gain On Sale Of Business | $0 | $40,390,000 | $0 | - |
| Impairment Of Capital Assets | $4,441,000 | $8,329,000 | $111,829,000 | $65,761,000 |
| Restructuring And Mergern Acquisition | $4,890,000 | $7,341,000 | $15,330,000 | $73,495,000 |
| Research And Development | $117,330,000 | $120,908,000 | $114,162,000 | $218,323,000 |
| Selling General And Administration | $68,673,000 | $76,751,000 | $77,417,000 | $92,333,000 |
| Other Gand A | $68,673,000 | $76,751,000 | $77,417,000 | $92,333,000 |
| Gain On Sale Of Ppe | - | $0 | $-1,300,000 | $3,326,000 |
| Other Special Charges | - | - | - | $10,898,000 |
| Gain On Sale Of Security | - | - | - | $33,427,000 |
| Write Off | - | - | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $89,832,000 | $60,737,000 | $130,987,000 | $290,137,000 |
| Total Assets | $280,406,000 | $303,850,000 | $398,033,000 | $710,600,000 |
| Total Non Current Assets | $14,140,000 | $42,558,000 | $67,332,000 | $164,632,000 |
| Other Non Current Assets | $5,648,000 | $4,647,000 | $4,644,000 | $2,245,000 |
| Investmentin Financial Assets | $0 | $13,869,000 | - | - |
| Current Assets | $266,266,000 | $261,292,000 | $330,701,000 | $545,968,000 |
| Prepaid Assets | $18,735,000 | $4,457,000 | $8,732,000 | $13,385,000 |
| Receivables | $1,779,000 | $1,609,000 | $2,252,000 | $8,404,000 |
| Other Receivables | $1,779,000 | $1,609,000 | $1,047,000 | $2,423,000 |
| Cash Cash Equivalents And Short Term Investments | $245,752,000 | $255,226,000 | $303,616,000 | $504,977,000 |
| Cash And Cash Equivalents | $15,116,000 | $44,252,000 | $35,277,000 | $88,227,000 |
| Inventory | - | $0 | $16,101,000 | $19,202,000 |
| Accounts Receivable | - | $0 | $1,205,000 | $5,981,000 |
| Goodwill And Other Intangible Assets | - | - | $0 | $76,501,000 |
| Other Current Assets | - | - | - | $15,808,000 |
| Cash Equivalents | - | - | - | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $85,751,000 | $102,564,000 | $117,776,000 | $131,496,000 |
| Long Term Debt And Capital Lease Obligation | $65,256,000 | $82,696,000 | $98,517,000 | $112,829,000 |
| Current Debt And Capital Lease Obligation | $20,495,000 | $19,868,000 | $19,259,000 | $18,667,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $190,574,000 | $243,113,000 | $267,046,000 | $343,962,000 |
| Total Non Current Liabilities Net Minority Interest | $137,038,000 | $181,713,000 | $215,777,000 | $275,758,000 |
| Other Non Current Liabilities | $71,782,000 | $99,017,000 | $117,260,000 | $162,929,000 |
| Current Liabilities | $53,536,000 | $61,400,000 | $51,269,000 | $68,204,000 |
| Payables And Accrued Expenses | $30,101,000 | $38,700,000 | $26,457,000 | $39,955,000 |
| Payables | $10,770,000 | $11,560,000 | $9,848,000 | $12,980,000 |
| Accounts Payable | $10,770,000 | $11,560,000 | $9,848,000 | $12,980,000 |
| Derivative Product Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $89,832,000 | $60,737,000 | $130,987,000 | $366,638,000 |
| Total Equity Gross Minority Interest | $89,832,000 | $60,737,000 | $130,987,000 | $366,638,000 |
| Stockholders Equity | $89,832,000 | $60,737,000 | $130,987,000 | $366,638,000 |
| Gains Losses Not Affecting Retained Earnings | $17,000 | $61,000 | $80,000 | $-6,907,000 |
| Other Equity Adjustments | $17,000 | $61,000 | $80,000 | $-6,907,000 |
| Retained Earnings | $-3,760,286,000 | $-3,596,210,000 | $-3,477,249,000 | $-3,201,193,000 |
| Long Term Equity Investment | $3,491,000 | $12,218,000 | $0 | - |
| Investments In Other Ventures Under Equity Method | $3,491,000 | $12,218,000 | $0 | - |
| Other | ||||
| Ordinary Shares Number | $20,378,832 | $12,385,133 | $12,758,933 | $12,570,666 |
| Share Issued | $20,378,832 | $12,937,466 | $12,758,933 | $12,570,666 |
| Tangible Book Value | $89,832,000 | $60,737,000 | $130,987,000 | $290,137,000 |
| Invested Capital | $89,832,000 | $60,737,000 | $130,987,000 | $366,638,000 |
| Working Capital | $212,730,000 | $199,892,000 | $279,432,000 | $477,764,000 |
| Capital Lease Obligations | $85,751,000 | $102,564,000 | $117,776,000 | $131,496,000 |
| Total Capitalization | $89,832,000 | $60,737,000 | $130,987,000 | $366,638,000 |
| Treasury Stock | $0 | $3,000,000 | $0 | - |
| Additional Paid In Capital | $3,850,099,000 | $3,659,885,000 | $3,608,137,000 | $3,574,719,000 |
| Capital Stock | $2,000 | $1,000 | $19,000 | $19,000 |
| Common Stock | $2,000 | $1,000 | $19,000 | $19,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $65,256,000 | $82,696,000 | $98,517,000 | $112,829,000 |
| Current Capital Lease Obligation | $20,495,000 | $19,868,000 | $19,259,000 | $18,667,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,940,000 | $2,832,000 | $5,553,000 | $9,582,000 |
| Current Accrued Expenses | $19,331,000 | $27,140,000 | $16,609,000 | $26,975,000 |
| Investments And Advances | $3,491,000 | $26,087,000 | $25,825,000 | $0 |
| Net PPE | $5,001,000 | $11,824,000 | $36,863,000 | $85,886,000 |
| Gross PPE | $5,001,000 | $11,824,000 | $123,761,000 | $210,617,000 |
| Other Properties | $5,001,000 | $11,824,000 | $56,859,000 | $102,730,000 |
| Other Short Term Investments | $230,636,000 | $210,974,000 | $268,339,000 | $416,750,000 |
| Treasury Shares Number | - | $552,333 | $0 | - |
| Other Investments | - | $13,869,000 | $25,825,000 | - |
| Available For Sale Securities | - | $13,869,000 | - | - |
| Accumulated Depreciation | - | $-15,910,000 | $-86,898,000 | $-124,731,000 |
| Construction In Progress | - | $245,000 | $739,000 | $2,530,000 |
| Machinery Furniture Equipment | - | $14,643,000 | $22,979,000 | $30,468,000 |
| Properties | - | $3,881,000 | $43,184,000 | $74,889,000 |
| Finished Goods | - | $0 | $1,360,000 | $5,878,000 |
| Work In Process | - | $0 | $12,880,000 | $10,749,000 |
| Raw Materials | - | $0 | $1,861,000 | $2,575,000 |
| Goodwill | - | - | $0 | $76,501,000 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-208,682,000 | $-177,177,000 | $-193,471,000 | $-309,683,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-208,511,000 | $-175,709,000 | $-192,606,000 | $-304,007,000 |
| Cash Flow From Continuing Operating Activities | $-208,511,000 | $-175,709,000 | $-192,606,000 | $-304,007,000 |
| Operating Gains Losses | $8,727,000 | $-40,390,000 | $6,399,000 | $-36,753,000 |
| Investing Activities | ||||
| Capital Expenditure | $-171,000 | $-1,468,000 | $-865,000 | $-5,676,000 |
| Investing Cash Flow | $-1,197,000 | $142,570,000 | $139,564,000 | $365,835,000 |
| Cash Flow From Continuing Investing Activities | $-1,197,000 | $142,570,000 | $139,564,000 | $365,835,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-3,000,000 | $0 | - |
| Issuance Of Capital Stock | $180,850,000 | $0 | - | - |
| Financing Cash Flow | $180,566,000 | $42,118,000 | $30,000 | $1,508,000 |
| Cash Flow From Continuing Financing Activities | $180,566,000 | $42,118,000 | $30,000 | $1,508,000 |
| Net Other Financing Charges | $-1,150,000 | $15,000,000 | - | $750,000 |
| Net Common Stock Issuance | $180,850,000 | $-3,000,000 | $0 | - |
| Common Stock Issuance | $180,850,000 | $0 | - | - |
| Other | ||||
| End Cash Position | $15,116,000 | $44,252,000 | $35,277,000 | $88,227,000 |
| Beginning Cash Position | $44,252,000 | $35,277,000 | $88,227,000 | $25,218,000 |
| Effect Of Exchange Rate Changes | $6,000 | $-4,000 | $62,000 | $-327,000 |
| Changes In Cash | $-29,142,000 | $8,979,000 | $-53,012,000 | $63,336,000 |
| Proceeds From Stock Option Exercised | $866,000 | $30,118,000 | $30,000 | $758,000 |
| Common Stock Payments | $0 | $-3,000,000 | $0 | - |
| Net Investment Purchase And Sale | $-329,000 | $78,652,000 | $139,184,000 | $358,315,000 |
| Sale Of Investment | $284,683,000 | $340,361,000 | $650,883,000 | $826,229,000 |
| Purchase Of Investment | $-285,012,000 | $-261,709,000 | $-511,699,000 | $-467,914,000 |
| Net Business Purchase And Sale | $-697,000 | $65,386,000 | $0 | - |
| Net PPE Purchase And Sale | $-171,000 | $-1,468,000 | $380,000 | $7,520,000 |
| Purchase Of PPE | $-171,000 | $-1,468,000 | $-865,000 | $-5,676,000 |
| Change In Working Capital | $-37,016,000 | $-6,239,000 | $-19,940,000 | $492,000 |
| Change In Other Working Capital | $-15,157,000 | $-12,905,000 | $-8,850,000 | $-2,680,000 |
| Change In Other Current Assets | $-15,449,000 | $-4,187,000 | $3,583,000 | $6,906,000 |
| Change In Payables And Accrued Expense | $-6,410,000 | $13,401,000 | $-20,148,000 | $-16,844,000 |
| Change In Accrued Expense | $-5,785,000 | $10,733,000 | $-17,264,000 | $-19,947,000 |
| Change In Payable | $-625,000 | $2,668,000 | $-2,884,000 | $3,103,000 |
| Change In Account Payable | $-625,000 | $2,668,000 | $-2,884,000 | $3,103,000 |
| Change In Inventory | $0 | $497,000 | $699,000 | $-3,401,000 |
| Change In Receivables | $0 | $-3,045,000 | $4,776,000 | $16,511,000 |
| Changes In Account Receivables | $0 | $-3,045,000 | $4,776,000 | $16,511,000 |
| Other Non Cash Items | $-28,748,000 | $-36,155,000 | $-43,587,000 | $-35,932,000 |
| Stock Based Compensation | $12,649,000 | $21,612,000 | $33,388,000 | $57,320,000 |
| Provisionand Write Offof Assets | $0 | $949,000 | $2,402,000 | $0 |
| Asset Impairment Charge | $4,441,000 | $8,329,000 | $111,829,000 | $65,761,000 |
| Amortization Of Securities | $-5,514,000 | $-9,245,000 | $-14,856,000 | $-2,435,000 |
| Depreciation Amortization Depletion | $1,026,000 | $4,391,000 | $7,815,000 | $13,030,000 |
| Depreciation And Amortization | $1,026,000 | $4,391,000 | $7,815,000 | $13,030,000 |
| Earnings Losses From Equity Investments | $8,727,000 | $0 | - | - |
| Gain Loss On Sale Of Business | $0 | $-40,390,000 | $0 | - |
| Net Income From Continuing Operations | $-164,076,000 | $-118,961,000 | $-276,056,000 | $-368,198,000 |
| Income Tax Paid Supplemental Data | - | $76,000 | $2,656,000 | $272,000 |
| Sale Of Business | - | $65,386,000 | $0 | - |
| Sale Of PPE | - | $0 | $1,245,000 | $13,196,000 |
| Net Foreign Currency Exchange Gain Loss | - | $0 | $5,099,000 | $0 |
| Gain Loss On Sale Of PPE | - | $0 | $1,300,000 | $-3,326,000 |
| Deferred Tax | - | - | $-140,000 | $2,708,000 |
| Deferred Income Tax | - | - | $-140,000 | $2,708,000 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | $-33,427,000 |
| Issuance Of Debt | - | - | - | - |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-18